Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

Detalles Bibliográficos
Autores principales: Durán, Javier, Estrada, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917040/
https://www.ncbi.nlm.nih.gov/pubmed/29726548
http://dx.doi.org/10.3389/fphar.2018.00381
_version_ 1783317118978097152
author Durán, Javier
Estrada, Manuel
author_facet Durán, Javier
Estrada, Manuel
author_sort Durán, Javier
collection PubMed
description
format Online
Article
Text
id pubmed-5917040
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59170402018-05-03 Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy Durán, Javier Estrada, Manuel Front Pharmacol Pharmacology Frontiers Media S.A. 2018-04-19 /pmc/articles/PMC5917040/ /pubmed/29726548 http://dx.doi.org/10.3389/fphar.2018.00381 Text en Copyright © 2018 Durán and Estrada. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Durán, Javier
Estrada, Manuel
Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
title Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
title_full Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
title_fullStr Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
title_full_unstemmed Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
title_short Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
title_sort commentary: blockade of activin type ii receptors with a dual anti-actriia/iib antibody is critical to promote maximal skeletal muscle hypertrophy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917040/
https://www.ncbi.nlm.nih.gov/pubmed/29726548
http://dx.doi.org/10.3389/fphar.2018.00381
work_keys_str_mv AT duranjavier commentaryblockadeofactivintypeiireceptorswithadualantiactriiaiibantibodyiscriticaltopromotemaximalskeletalmusclehypertrophy
AT estradamanuel commentaryblockadeofactivintypeiireceptorswithadualantiactriiaiibantibodyiscriticaltopromotemaximalskeletalmusclehypertrophy

Ejemplares similares